JP6901823B2 - 間葉系幹細胞による肺動脈性高血圧症の処置 - Google Patents

間葉系幹細胞による肺動脈性高血圧症の処置 Download PDF

Info

Publication number
JP6901823B2
JP6901823B2 JP2015525508A JP2015525508A JP6901823B2 JP 6901823 B2 JP6901823 B2 JP 6901823B2 JP 2015525508 A JP2015525508 A JP 2015525508A JP 2015525508 A JP2015525508 A JP 2015525508A JP 6901823 B2 JP6901823 B2 JP 6901823B2
Authority
JP
Japan
Prior art keywords
cells
msc
cell
prostacyclin
epc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015525508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524437A (ja
Inventor
ジェフズ，ロジャー
ピーターセン，トーマス
イラガン，ロジャー，エム．
ウェイド，マイケル
Original Assignee
ユナイテッド セラピューティクス コーポレイション
ユナイテッド セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレイション, ユナイテッド セラピューティクス コーポレイション filed Critical ユナイテッド セラピューティクス コーポレイション
Publication of JP2015524437A publication Critical patent/JP2015524437A/ja
Application granted granted Critical
Publication of JP6901823B2 publication Critical patent/JP6901823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015525508A 2012-08-01 2013-07-30 間葉系幹細胞による肺動脈性高血圧症の処置 Active JP6901823B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261678207P 2012-08-01 2012-08-01
US61/678,207 2012-08-01
US201361750458P 2013-01-09 2013-01-09
US61/750,458 2013-01-09
PCT/US2013/052695 WO2014022373A1 (en) 2012-08-01 2013-07-30 Treatment of pulmonary arterial hypertension with mesenchymal stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019045535A Division JP2019123726A (ja) 2012-08-01 2019-03-13 間葉系幹細胞による肺動脈性高血圧症の処置

Publications (2)

Publication Number Publication Date
JP2015524437A JP2015524437A (ja) 2015-08-24
JP6901823B2 true JP6901823B2 (ja) 2021-07-14

Family

ID=50028470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015525508A Active JP6901823B2 (ja) 2012-08-01 2013-07-30 間葉系幹細胞による肺動脈性高血圧症の処置
JP2019045535A Pending JP2019123726A (ja) 2012-08-01 2019-03-13 間葉系幹細胞による肺動脈性高血圧症の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019045535A Pending JP2019123726A (ja) 2012-08-01 2019-03-13 間葉系幹細胞による肺動脈性高血圧症の処置

Country Status (11)

Country Link
US (2) US10071123B2 (Direct)
EP (1) EP2879682B1 (Direct)
JP (2) JP6901823B2 (Direct)
KR (1) KR102143255B1 (Direct)
CN (2) CN104684561A (Direct)
AU (2) AU2013296611B2 (Direct)
CA (1) CA2880808C (Direct)
ES (1) ES2671932T3 (Direct)
IL (1) IL237021B (Direct)
IN (1) IN2015DN00934A (Direct)
WO (1) WO2014022373A1 (Direct)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN00976A (Direct) 2012-08-01 2015-06-12 United Therapeutics Corp
US20160175360A1 (en) * 2012-12-12 2016-06-23 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
EP3878452B1 (en) * 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014110491A1 (en) 2013-01-11 2014-07-17 Theratrophix Llc Prodrugs of treprostinil
EP3808731A1 (en) 2013-10-25 2021-04-21 Insmed Incorporated Prostacyclin compounds
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
KR101843634B1 (ko) * 2016-04-15 2018-03-30 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
US10946047B2 (en) 2016-06-17 2021-03-16 United Therapeutics Corporation Extracellular vesicles with enhanced potency
CN110022887A (zh) * 2016-06-17 2019-07-16 联合治疗学有限公司 具有增强效力的细胞外囊泡
KR102606101B1 (ko) * 2016-10-24 2023-11-27 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐에 의한 msc 면역조절 특성의 향상
WO2018119185A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for increasing heme oxygenase level
US11911349B2 (en) 2018-03-30 2024-02-27 Nattopharma As Rapidly improving vascular conditions by administering vitamin K
CN113490412B (zh) 2018-10-05 2023-07-28 药物治疗股份有限公司 异种移植制品和方法
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
AU2020265576B2 (en) 2019-04-29 2025-09-18 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
EP4285915A1 (en) * 2022-06-03 2023-12-06 Medizinische Hochschule Hannover Human mesenchymal stem cell-conditioned medium for use in treatment of chronic heart-lung and vascular diseases, in particular, of pulmonary arterial hypertension (pah)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5026365A (en) 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5071741A (en) 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
EP0624190A4 (en) 1992-01-21 1995-04-19 Cryopharm Corp METHOD FOR FREEZING CELLS AND CELL-LIKE MATERIALS.
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
JP4098355B2 (ja) 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
JP3591837B2 (ja) 1994-02-17 2004-11-24 ニューヨーク・ブラッド・センター・インコーポレイテッド フィブリン膠およびリポソームを含有する生物学的生体接着剤組成物、その製造方法および使用
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5580714A (en) 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5629145A (en) 1995-03-24 1997-05-13 Organ, Inc. Cryopreservation of cell suspensions
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
AU1333797A (en) 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
WO1998014058A1 (en) 1996-10-03 1998-04-09 The Regents Of The University Of California Cryopreservation of human adult and fetal pancreatic cells and human platelets
ES2235227T3 (es) 1996-11-01 2005-07-01 Ark Therapeutics Limited Utilizacion de vegf para la preparacion de un medicamento destinado al tratamiento o prevencion de la hiperplasia intimal y dispositivo para su administracion.
ATE307195T1 (de) 1997-07-14 2005-11-15 Osiris Therapeutics Inc Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
US9585916B2 (en) * 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US9320829B2 (en) 2000-03-15 2016-04-26 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU7362301A (en) 2000-06-22 2002-01-02 Sam L Austin Bioadhesive compositions and methods of preparation and use
AU2003297592A1 (en) 2002-11-30 2004-06-23 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
EP2348105B1 (en) 2004-09-24 2018-10-24 Mesoblast, Inc. Multipotential expanded mesenchymal precursor cell progeny (MEMP) and uses thereof
WO2007022515A2 (en) 2005-08-19 2007-02-22 Duke University Stem cell derived factors for treating pathologic conditions
US20070065414A1 (en) 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
EP1971681B1 (en) * 2005-12-16 2017-08-23 DePuy Synthes Products, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
WO2007124594A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
US20100040584A1 (en) * 2006-12-19 2010-02-18 Children's Medical Center Corporation Methods for promoting neovascularization
KR20150039214A (ko) * 2007-02-12 2015-04-09 안트로제네시스 코포레이션 태반 줄기세포를 이용한 염증 질환의 치료
JP2011015609A (ja) * 2007-10-30 2011-01-27 Asahikawa Medical College 内皮前駆細胞（ｅｐｃ）の増殖・分化誘導方法
HRP20150510T1 (hr) 2008-02-22 2015-06-05 Agency For Science, Technology, And Research (A*Star) Äśestice mezenhimskih matiäśnih stanica
CA2842181C (en) 2010-08-27 2021-01-05 University Of Miami Bone marrow derived cd271 precursor cells for cardiac repair
AU2012206517B2 (en) 2011-01-13 2016-12-01 Scipharm Sarl Method for Enhancing Engraftment of Haematopoietic Stem Cells
DK2760994T4 (da) * 2011-09-30 2021-10-11 Bluebird Bio Inc Forbindelser til forøget viral transduktion
IN2015DN00976A (Direct) 2012-08-01 2015-06-12 United Therapeutics Corp
EP3878452B1 (en) 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Also Published As

Publication number Publication date
EP2879682B1 (en) 2018-03-21
AU2013296611B2 (en) 2017-11-23
IN2015DN00934A (Direct) 2015-06-12
US20150246078A1 (en) 2015-09-03
US20190008904A1 (en) 2019-01-10
AU2018201231B2 (en) 2019-12-05
US10071123B2 (en) 2018-09-11
CN104684561A (zh) 2015-06-03
EP2879682A1 (en) 2015-06-10
AU2013296611A1 (en) 2015-03-05
KR20150038162A (ko) 2015-04-08
CA2880808A1 (en) 2014-02-06
JP2019123726A (ja) 2019-07-25
JP2015524437A (ja) 2015-08-24
IL237021B (en) 2018-02-28
AU2018201231A1 (en) 2018-03-15
KR102143255B1 (ko) 2020-08-10
CA2880808C (en) 2023-01-24
ES2671932T3 (es) 2018-06-11
WO2014022373A1 (en) 2014-02-06
EP2879682A4 (en) 2016-03-16
CN111803523A (zh) 2020-10-23
US11666602B2 (en) 2023-06-06

Similar Documents

Publication Publication Date Title
JP6901823B2 (ja) 間葉系幹細胞による肺動脈性高血圧症の処置
US12274684B2 (en) Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
JP6810717B2 (ja) プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190313

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190313

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190402

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190522

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190528

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190726

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190730

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200128

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201027

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210427

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210601

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210618

R150 Certificate of patent or registration of utility model

Ref document number: 6901823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250